Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Addex Therapeutics
< Previous
1
2
Next >
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
April 17, 2025
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at the 2025 Swiss Equities Baader Conference
January 08, 2025
From
Addex Therapeutics
Via
GlobeNewswire
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 22, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
November 11, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
September 30, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
September 19, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
August 27, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex’s Partner Discontinues ADX71149 development in Epilepsy
July 22, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
July 15, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
July 12, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Shareholders Approve All Resolutions at Annual General Meeting
July 01, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
June 06, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Convenes Annual General Meeting 2024
June 05, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
May 31, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at Bio€quity Europe 2024
May 08, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
April 29, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at the Swiss Biotech Day 2024
April 19, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
April 18, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
April 11, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
April 03, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at the Bio-Europe Spring 2024 Conference
March 14, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
January 31, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at the Swiss Equities Baader Conference
January 09, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at Biotech Showcase™ 2024
January 05, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
December 20, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Creates Treasury Shares
December 14, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
November 29, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Convenes Extraordinary General Meeting
November 28, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
November 23, 2023
From
Addex Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
